SEEDING SCIENCE

Their core work

Seeding Science is a Paris-based SME operating at the intersection of oncology research and scientific infrastructure. Their H2020 work spans two distinct but complementary tracks: contributing to rare cancer therapy development (uveal melanoma) and helping build shared European infrastructure for patient-derived cancer xenograft (PDX) models. In the EDIReX project they were involved in the management, standardization, and dissemination activities of a distributed biobank network — roles typical of a science management or research support firm rather than a pure wet-lab. Their profile suggests they offer project coordination support, scientific communication, and access facilitation services to cancer research consortia.

What they specialise in

How they've shifted over time

Their first project (UM Cure 2020, starting 2016) focused on therapeutic development for a specific rare cancer, with no recorded infrastructure or management keywords — suggesting a research-facing or clinical support role. By 2018, with EDIReX, the focus shifted markedly toward research infrastructure: biobanks, standards, repositories, and trans-national access — the language of science management and coordination rather than bench research. With only two projects it is hard to call this a firm trend, but the direction points from disease-specific research participation toward enabling infrastructure and dissemination roles in cancer research networks.

Seeding Science appears to be moving toward a role as a research infrastructure enabler and dissemination specialist within oncology consortia, making them a potential partner for projects needing scientific communication, biobank access facilitation, or trans-national coordination support.

How they like to work

Seeding Science has participated exclusively as a consortium partner — never as project coordinator — across both H2020 projects. They engage in mid-to-large consortia (28 unique partners across 14 countries) and bring specialist contributions rather than overall project leadership. This profile is consistent with an SME that embeds itself in larger research networks, delivering defined workpackage outputs such as dissemination, training, or infrastructure management, rather than driving the scientific agenda.

Seeding Science has built a network of 28 unique partners across 14 countries through just two projects — a notably broad reach for a two-project portfolio, reflecting participation in large pan-European consortia. Their network is concentrated in health and research infrastructure circles, with no evidence of repeat partnerships given the small project count.

What sets them apart

Seeding Science occupies a rare niche as a private French SME bridging oncology research and research infrastructure — combining disease-specific expertise (rare cancers, PDX models) with operational roles in biobank standardization and trans-national access. For consortium builders, they offer the credibility of oncology research participation alongside the practical value of a science management SME comfortable with dissemination and training workpackages. Their small size and Paris base make them a flexible, cost-efficient partner for EU projects needing targeted oncology expertise without a large academic overhead.

Highlights from their portfolio

• EDIReX
  The larger of the two projects (EUR 294,434), EDIReX built a distributed European infrastructure for patient-derived cancer xenograft research — a high-impact initiative linking biobanks, standards, and trans-national access across multiple countries.
• UM Cure 2020
  Focused on uveal melanoma — one of the rarest and deadliest ocular cancers — demonstrating Seeding Science's engagement with niche, high-unmet-need therapeutic areas from an early stage.